Review of Carboplatin-Based High-Dose Chemotherapy Combinations in the Autotransplant Setting

  • S. Rodenhuis
  • E. van der Wall
  • J. H. Schornagel
  • J. W. Baars


High-dose chemotherapy is a relatively straightforward approach to overcome drug resistance. It appears to be more effective than standard chemotherapy in the salvage treatment of Non Hodgkin’s Lymphomas and of relapsing germ cell cancer. Non-randomized studies have raised hope that it might improve treatment results in (other) solid tumors as well, particularly in the adjuvant treatment of high-risk breast cancer1. Prospective, randomized studies of high-dose therapy are currently in progress, but many more will be required to define its proper role in solid tumors.


Clin Oncol Peripheral Blood Stem Cell Autologous Bone Marrow Autologous Bone Marrow Transplantation Hemorrhagic Cystitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–43.PubMedGoogle Scholar
  2. 2.
    Vaner Wall E, Beijnen JH, Rodenhuis S. High-dose chemotherapy regimens for solid tumors: a review. Cancer Treatm Rev 1995; in press.Google Scholar
  3. 3.
    Frei II, E, Antman K, Teicher B, Eder P, Schnipper L. Bone marrow autotransplantation for solid tumors — prospects. J Clin Oncol 1989; 7: 515–26.PubMedGoogle Scholar
  4. 4.
    O’Dwyer PJ, LaCreta F, Engstrom PF, Peter R, Tartaglia L, Cole D, Litwin S, DeVito J, Poplack D, DeLap RJ, Comis RL. Phase I pharmacokinetic reevaluation of ThioTEPA. Cancer Res 1991; 51: 3171–76.PubMedGoogle Scholar
  5. 5.
    Martin M, Diaz-Rubio E, Casado A, Santabárbara P, Manuel López Vega J, Adrover E, Lenaz L: Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 1992; 10: 433–7.PubMedGoogle Scholar
  6. 6.
    O’Brien MER, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a phamacokinetically guided dose schedule. J Clin Oncol 1993; 11: 2112–17.PubMedGoogle Scholar
  7. 7.
    Nichols CR, Tricot G, Williams SD, Van Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN, Giannone L, Greer J, Einhorn LH, Jansen J. Dose-intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932–9.PubMedGoogle Scholar
  8. 8.
    Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, Loehrer PJ, Trump DL. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group Protocol. J Clin Oncol 1992; 10: 558–63.PubMedGoogle Scholar
  9. 9.
    Broun ER, Nichols CR, Tricot G, Loehrer PJ, Williams SD, Einhorn LH. High-dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant 1991; 7:53–6.PubMedGoogle Scholar
  10. 10.
    Rosti G, Albertazzi L, Salvioni R, Pizzocaro G, Cetto GL, Bassetto MA, Marangolo M. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study. Ann Oncol 1992; 3: 809–12.PubMedGoogle Scholar
  11. 11.
    Lotz JP, Machover D, Malassagne B, Hingh B, Donsimoni R, Gumus Y, Gerota J, Lam Y, Tulliez M, Marsiglia H, Mauban S, Izrael V. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J Clin Oncol 1991; 9: 1860–70.PubMedGoogle Scholar
  12. 12.
    Shea TC, Storniolo AM, Mason JR, Newton B, Mullen M, Taetle R, Green MR. A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue. Semin Oncol 1992; 19(Suppl 2): 139–44.PubMedGoogle Scholar
  13. 13.
    Motzer RJ, Gulati SC, Tong WP, Menendez-Botet C, Lyn P, Mazumdar M, Vlamis V, Lin S, Bosl G. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res 1993; 53: 3730–35.PubMedGoogle Scholar
  14. 14.
    Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E III, Antman K. A phase I-II study of cyclophosphamide, thiotepa and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239–45.PubMedGoogle Scholar
  15. 15.
    Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei E III. A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 1992; 10: 102–10.PubMedGoogle Scholar
  16. 16.
    Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J, Flaherty M, Mick R, Schnipper LE, Frei E III. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst 1988; 80: 1221–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, Schnipper L, Frei E III, Antman K. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37–44.PubMedGoogle Scholar
  18. 18.
    Rodenhuis S, Baars JW, Schornagel JH, Vlasveld LT, Mandjes I, Pinedo HM, Richel DJ. Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, thiotepa and cyclophosphamide. Ann Oncol 1992; 3: 855–60.PubMedGoogle Scholar
  19. 19.
    Van er Wall E, Nooijen WJ, Baars JW, Holtkamp MJ, Schornagel JH, Richel DJ, Rutgers EJT, Slaper-Cortenbach ICM, Van der Schoot CE, Rodenhuis S. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 1995; in press.Google Scholar
  20. 20.
    Rodenhuis, Van der Wall E, Ten Bokkel Huinink WW, Schornagel JH, Richel DJ, Vlasveld LT. Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. Cancer Invest 1995; in press.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • S. Rodenhuis
    • 1
  • E. van der Wall
    • 1
  • J. H. Schornagel
    • 1
  • J. W. Baars
    • 1
  1. 1.Department of Medical OncologyThe Netherlands Cancer InstituteAmsterdamThe Netherlands

Personalised recommendations